Read more

Selexipag: First Global Approval.

Related ArticlesSelexipag: First Global Approval.
Drugs. 2016 Feb 4;
Authors: Scott LJ
Abstract
Selexipag (Uptravi(®)) is a highly selective, long-acting, nonprostanoid, prostacyclin receptor agonist that …